Neuromodulation and female sexual function

Does treatment for refractory voiding symptoms have an added benefit?

Michael Ingber, Ibrahim A. Ibrahim, Kim A. Killinger, Ananias C. Diokno, Kenneth M. Peters

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

Original languageEnglish (US)
Pages (from-to)1055-1059
Number of pages5
JournalInternational Urogynecology Journal
Volume20
Issue number9
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Interstitial Cystitis
Overactive Urinary Bladder
Therapeutics
Databases
Population

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology
  • Urology

Cite this

Ingber, Michael ; Ibrahim, Ibrahim A. ; Killinger, Kim A. ; Diokno, Ananias C. ; Peters, Kenneth M. / Neuromodulation and female sexual function : Does treatment for refractory voiding symptoms have an added benefit?. In: International Urogynecology Journal. 2009 ; Vol. 20, No. 9. pp. 1055-1059.
@article{be482b74169c4ac89354009bcad6cf9a,
title = "Neuromodulation and female sexual function: Does treatment for refractory voiding symptoms have an added benefit?",
abstract = "Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.",
author = "Michael Ingber and Ibrahim, {Ibrahim A.} and Killinger, {Kim A.} and Diokno, {Ananias C.} and Peters, {Kenneth M.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1007/s00192-009-0900-3",
language = "English (US)",
volume = "20",
pages = "1055--1059",
journal = "International Urogynecology Journal and Pelvic Floor Dysfunction",
issn = "0937-3462",
publisher = "Springer London",
number = "9",

}

Neuromodulation and female sexual function : Does treatment for refractory voiding symptoms have an added benefit? / Ingber, Michael; Ibrahim, Ibrahim A.; Killinger, Kim A.; Diokno, Ananias C.; Peters, Kenneth M.

In: International Urogynecology Journal, Vol. 20, No. 9, 01.01.2009, p. 1055-1059.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neuromodulation and female sexual function

T2 - Does treatment for refractory voiding symptoms have an added benefit?

AU - Ingber, Michael

AU - Ibrahim, Ibrahim A.

AU - Killinger, Kim A.

AU - Diokno, Ananias C.

AU - Peters, Kenneth M.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

AB - Introduction and hypothesis: Women undergoing InterStim implantation for overactive bladder (OAB) or painful bladder syndrome (PBS) were prospectively evaluated to determine if neuromodulation has any effect on female sexual function (FSF). Methods: Sexually active women in our InterStim database completed a female sexual function index (FSFI) preoperatively and at 6 months. Results: Of 105 women, 54 have 6-month follow-up data. Of these, 27 were sexually active preoperatively and at follow-up. The mean (standard deviation (SD)) FSFI improved from 18.7 (6.8) preoperatively to 21.0 (6.0) postoperatively; however, this was not statistically significant (p = 0.220). Subgroup analysis of patients with OAB revealed that mean (SD) FSFI preoperatively was 18.6 (8.0) and 22.4 (6.4) at 6 months (p = 0.257). In the PBS group, mean (SD) FSFI was 18.8 (6.3) preoperatively and 18.7 (5.8) at 6 months (p = 0.98). Conclusions: Neuromodulation does not significantly improve FSF in a heterogenous population. Additional studies are needed to confirm the findings in our study.

UR - http://www.scopus.com/inward/record.url?scp=70350450720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350450720&partnerID=8YFLogxK

U2 - 10.1007/s00192-009-0900-3

DO - 10.1007/s00192-009-0900-3

M3 - Article

VL - 20

SP - 1055

EP - 1059

JO - International Urogynecology Journal and Pelvic Floor Dysfunction

JF - International Urogynecology Journal and Pelvic Floor Dysfunction

SN - 0937-3462

IS - 9

ER -